ArticleOncogene2026
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Kirsten rat sarcoma viral oncogene (KRAS) G12C inhibitors have demonstrated clinical efficacy against KRAS G12C-mutant non-small cell lung cancer (NSCLC); however, intrinsic and acquired resistance limit their therapeutic potential. Therefore, combination strategies are needed to address these limitations. While various combination regimens are currently being tested in clinical trials, treatments tailored to specific biomarkers remain underexplored. In this study, intrinsic and acquired KRAS G12C inhibitor-resistant tumor cells were established using patient-derived xenograft (PDX) and mouse models. We identified that tumor cell-autocrine amphiregulin (AREG)-mediated epidermal growth factor receptor (EGFR) phosphorylation plays a pivotal role in both intrinsic and acquired resistance to KRAS inhibitors. Notably, the same resistance mechanism was observed in central nervous system metastatic recurrence in a leptomeningeal carcinomatosis mouse model. RNAscope in situ hybridization detected AREG mRNA in tumor tissues and may serve as a diagnostic tool for assessing AREG expression. Furthermore, combining KRAS inhibitors with EGFR tyrosine kinase inhibitors suppressed tumor growth, effectively overcoming resistance. Notably, high AREG mRNA expression was observed in three of nine tumor samples from patients harboring the KRAS G12C mutation, including two patients who exhibited a poor response to sotorasib and one patient who achieved a partial response. In conclusion, AREG-mediated EGFR activation is a key driver of resistance to KRAS inhibitors in patients with KRAS G12C-mutant NSCLC. Combining EGFR and KRAS inhibition represents a promising strategy to overcome therapeutic resistance and may enhance and prolong clinical benefit in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.